Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterMune Wagers On Pirfenidone With Sale Of Full Danoprevir Rights To Roche

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech gets $175 million for HCV protease inhibitor for which some analysts had prescribed no net present value.

You may also be interested in...



BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

Pleasant Surprise For InterMune With Early Positive Opinion On Pirfenidone From CHMP

With approval in EU nearly certain for IPF drug, InterMune's share price more than doubles.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel